How a Bay Area biotech uncovered a potential Covid fighter — and why it later dumped it

"This is the most important disease in my lifetime and we had a biology that was applicable,” said the co-founder, president and CEO of the Peninsula drug developer. But it couldn't get enough patients for a trial.